Kevin is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry.
Kevin Buchan
Latest news
-
Reflecting on our commitment to involve patients and the public in our work
-
Reflections from the LifeArc Translational Science Summit on MND and Rare Dementias
-
LifeArc and Neuropeutics Inc join forces to advance a new treatment for MND/ALS